Table 1.
Epidemiological, demographic, and clinical characteristics of the 99 hospitalized patients with COVID-19 infection.
| Parameters | All (n = 99) | Improving (n = 64) | Worsening (n = 35) | P-value |
|---|---|---|---|---|
| Age, years | 65 [51.5–75.0] | 63 [48.8–74.3] | 71 [59.0–76.0] | 0.044 |
| Male | 53 (54%) | 30 | 23 | 0.113 |
| Body mass index, kg/m2 | 27.8 [24.0–32.0] | 26.9 [23.8–31.0] | 28.4 [24.5–32.8] | 0.255 |
| Underlying comorbidity | ||||
| Chronic obstructive pulmonary disease | 7 (7.1%) | 4 (6.3%) | 3 (8.6%) | 0.695 |
| Asthma | 10 (10.1%) | 6 (9.4%) | 4 (11.4%) | 0.739 |
| Other respiratory disease | 9 (9.1%) | 7 (10.9%) | 2 (5.7%) | 0.486 |
| Diabetes | 30 (30.3%) | 16 (25.0%) | 14 (40.0%) | 0.186 |
| Hypertension | 52 (52.5%) | 30 (46.9%) | 22 (62.9%) | 0.190 |
| Chronic kidney disease (eGFR <30 ml/min) | 9 (9.1%) | 5 (7.8%) | 4 (11.4%) | 0.717 |
| Chronic heart failure | 4 (4.1%) | 2 (3.1%) | 2 (5.7%) | 0.613 |
| Previous drug use | ||||
| Immunosuppressant drugs | 7 (7.1%) | 3 (4.7%) | 4 (11.4%) | 0.240 |
| Anticoagulation | ||||
| None | 53 (53.5%) | 44 (68.8%) | 9 (25.7%) | <0.001 |
| Standard | 25 (25.3%) | 13 (20.3%) | 12 (34.3%) | |
| Enhanced | 13 (13.1%) | 5 (7.8%) | 8 (22.9%) | |
| Curative | 8 (8.1%) | 2 (3.1%) | 6 (17.1%) | |
| O2 requirement on admission | 73 (73.7%) | 40 (62.5%) | 33 (94.3%) | <0.001 |
| Smoking history | ||||
| Never/Former smokers | 84 (84.8%) | 54 (84.4%) | 30 (85.7%) | 1.000 |
| Current smokers | 15 (15.2%) | 10 (15.6%) | 5 (14.3%) | |
| Hospitalization duration | 12.0 [6.0–19.0] | 9.0 [5.5–14.0] | 18.0 [8.5–25.5] | 0.002 |
| Hospitalization delay since the onset of symptoms | 7.0 [4.0–10.0] | 7.0 [4.0–10.0] | 6.0 [4.0–7.0] | 0.195 |
| Radiological injuries | ||||
| None | 3/86 (3.5%) | 2/54 (3.7%) | 1/32 (3.1%) | 0.009 |
| Not suggestive | 3/86 (3.5%) | 3/54 (5.6%) | 0/32 (0.0%) | |
| <10% | 11/86 (12.8%) | 9/54 (16.7%) | 2/32 (6.3%) | |
| 10–25% | 39/86 (45.3%) | 29/54 (53.7%) | 10/32 (31.3%) | |
| 25–50% | 15/86 (17.4%) | 5/54 (9.3%) | 10/32 (31.3%) | |
| 50–75% | 13/86 (15.1%) | 6/54 (11.1%) | 7/32 (21.9%) | |
| >75% | 2/86 (2.3%) | 0/54 (0.0%) | 2/32 (6.3%) | |
| Radiological condensation | ||||
| None | 22/82 (26.8%) | 17/52 (32.7%) | 5/30 (16.7%) | 0.427 |
| Nodular | 17/82 (20.7%) | 10/52 (19.2%) | 7/30 (23.3%) | |
| Linear | 37/82 (45.1%) | 22/52 (42.3%) | 15/30 (50.0%) | |
| Linear and nodular | 6/82 (7.3%) | 3/52 (5.8%) | 3/30 (10%) | |
| Radiological abnormalities localization | ||||
| None | 10/81 (12.3%) | 8/51 (15.7%) | 2/30 (6.6%) | 0.554 |
| Unilateral | 3/81 (3.7%) | 2/51 (3.9%) | 1/30 (3.3%) | |
| Bilateral | 68/81 (84%) | 41/51 (80.4%) | 27/30 (90.0%) | |
| Thrombosis | 8 (8.1%) | 3 (4.7%) | 5 (14.3%) | 0.127 |
| SARS-CoV-2 nucleic acid test pre-admission | 81 (81.8%) | 50 (78.1%) | 31 (88.6%) | 0.278 |
Data are expressed as median [IQR], n (%), or n/N (%), where N is the total number of patients with available data. Escalated anticoagulation corresponding to 4,000 UI twice a day of enoxaparin, 6,000 UI twice a day of enoxaparin if body weight > 120 kg, or 200 UI/kg of unfractionated heparin. Lymphocytes <1 G/L, monocytes <0.2 G/L, VWF, GPIb-binding activity >250%, Prothrombin fragment 1+2 >290 pM are outside values range. P-values comparing clinical improvement to clinical worsening are from χ2 test, Fisher's exact test, or Mann–Whitney U-test. DIC, disseminated intravascular coagulation; ISTH, international society of thrombosis and haemostasis; TGA, thrombin generation assay.
Bold values are significant values.